Hims & Hers CEO Andrew Dudum (Business Wire)

Hims expands into testosterone treatments

The company will start with compounded enclomiphene, with more treatments to come in 2026.

9/10/25 9:00AM

Hims & Hers rose more than 5% on Wednesday morning after it announced that it has expanded into testosterone treatments after teasing the new category earlier this year.

Starting Wednesday, Hims providers will be able to prescribe compounded enclomiphene, an oral off-label testosterone treatment, which the company says it can combine with tadalafil, a treatment for erectile dysfunction. Hims also said that it plans next year to introduce injectable testosterone and partner with Marius Pharmaceuticals to provide Kyzatrex, a branded and FDA-approved oral testosterone treatment.

Investors have been eager for signs of revenue growth at Hims. In its annual shareholder letter, Hims said it would expand into hormone treatments for testosterone and menopause by the end of the year.

Hims patients will start with an at-home blood test. In February, the company acquired Trybe Labs, a blood-testing facility that gives patients results in days. Prescriptions for enclomiphene will be dispensed by both partner and Hims-owned pharmacies.

I tried signing up for a prescription of compounded enclomiphene (which is not available in New York, where I live) and was quoted $990 for a 10-month plan, which includes the cost of the at-home tests.

Hims saw a boom in compounded GLP-1 sales while those branded drugs were in shortage, but since the supply constraints eased earlier this year, the company has been limited in how much of the blockbuster weight-loss drugs it can sell. Last month, it reported quarterly revenue numbers that missed Wall Street estimates and fell quarter to quarter for the first time ever.

The partnership with Marius also helps bolster the company’s vision as the “Netflix of healthcare” — a narrative that got dimmed after its epic falling out with Novo Nordisk. The exclusivity of the partnership with Marius “pertains specifically to the private label aspect of the partnership,” a spokesperson for the pharmaceutical company told Sherwood News.

Luke Kawa

7/13/26

Meet the newly public, Bezos-backed company that’s recreating the sun and stars

General Fusion CEO Greg Twinney spoke with Sherwood News from the Nasdaq during the stock’s first day of trading.

J. Edward Moreno7/7/26

SpaceX gets a wave of bullish ratings from Wall Street analysts

SpaceX received more than a dozen positive analyst calls on Tuesday — including from major Wall Street banks — as they initiate coverage on Elon Musk’s space and AI company.

SpaceX went public on June 12 at a $2.2 trillion valuation, the largest debut in history. While the company hasn’t yet posted a profit, it seems to have convinced Wall Street that it will get there and grow its valuation on the way.

Of the at least 17 analysts that gave a rating on Tuesday, all but one gave it a “buy” or “outperform” rating. MoffettNathanson was "neutral."

The ratings come as SpaceX joined the Nasdaq 100 index, a benchmark tech-heavy basket of companies that underpins millions of portfolios. The inclusion adds built-in demand for the stock from index funds and ETFs.

Still, SpaceX fell more than 5% on Tuesday amid a broader sell-off, and is currently effectively flat from its opening price of $150 a share.

Luke Kawa

7/2/26

US job growth falls far short of estimates in June; unemployment rate unexpectedly dips to 4.2%

Job growth was 57,000. Analysts foresaw job growth of 113,000; prediction markets were more optimistic, looking for job growth above 125,000 but below 150,000.

Floridians Seek Employment Opportunities At Job Fair In Sunrise

Luke Kawa

7/1/26

Meta surges on report it’s starting a cloud business to sell excess AI compute

The story of the hyperscalers in 2026 has largely been “the beatings will continue until the cash flow outlook improves;” this could help change the story for Meta. Or not.

Meta CEO Mark Zuckerberg visits U.S. Capitol for Senate meetings

Paige Oamek6/30/26

Nike sinks to lowest level since 2014 after warning of “challenged” sales environment in Q4 report

Did Nike do it?

Investors had a mixed reaction after the global sports apparel company reported its fourth quarter earnings on Tuesday after the bell. Shares initially rose 5% as Nike beat out Wall Street expectations amid a hefty tariff refund bonus. However, the stock then sank to its lowest level since August 2014 in postmarket trading.

Here are the Q4 numbers:

Revenue of $11.0 billion (estimate: $10.8 billion).
Adjusted earnings per share of $0.20 (estimate: $0.12).

Ahead of this report, Nike warned that results would be flattered by a one-time tariff refund (now estimated at roughly $0.52 per share for the bottom line). That gave the company an extra cushion in snapping its streak of seven quarters of year-over-year profit declines.

Over the past year, the company had been punished by tariffs on imported goods, stagnant consumer spending, and increasing competition from other footwear brands like New Balance, Adidas, and Hoka.

Outgoing CFO Matthew Friend deemed it an “increasingly challenging operating environment, where sell-through remains challenged.”

Hims expands into testosterone treatments

More Markets

SpaceX gets a wave of bullish ratings from Wall Street analysts

Nike sinks to lowest level since 2014 after warning of “challenged” sales environment in Q4 report

Latest Stories